XML 14 R5.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Operating activities:    
Net loss $ (99,835) $ (162,155)
Adjustments to reconcile net loss to net cash used in operating activities:    
Stock-based compensation expense 28,530 32,466
Depreciation and amortization 2,184 2,098
Amortization of debt discount 21  
Amortization of debt issuance costs 155 152
Accretion of discount on short-term investments (1,173) (162)
Impairment of property and equipment 463 130
Loss on disposal of property and equipment 23 74
Change in operating assets and liabilities:    
Accounts receivable (11,746) (6,689)
Inventory 12,566 (3,857)
Prepaid expenses and other assets 10,541 5,726
Accounts payable (1,365) 2,744
Accrued clinical and manufacturing liabilities 272 13,582
Accrued payroll and employee liabilities (3,040) (555)
Other accrued and other non-current liabilities 1,160 7,068
Net cash used in operating activities (61,244) (109,378)
Investing activities:    
Purchases of short-term investments (64,309) (127,115)
Maturities and sales of short-term investments 92,435 122,957
Purchases of property and equipment (1,295) (1,411)
Proceeds from the sale of property and equipment   224
Net cash provided by (used in) investing activities 26,831 (5,345)
Financing activities:    
Net proceeds from private placement 29,755 75,163
Net proceeds from note financing 24,350  
Payments for stock issued under the equity incentive plan (901) (1,315)
Proceeds from purchases under the employee stock purchase plan 704 772
Net cash provided by financing activities 53,908 74,620
Net increase (decrease) in cash and cash equivalents 19,495 (40,103)
Cash and cash equivalents at beginning of year 15,364 90,541
Cash and cash equivalents at end of period 34,859 50,438
Supplemental disclosure of cash flow information:    
Interest paid $ 1,288 $ 1,125